SCHEMBL1761868

SCHEMBL1761868

CC(C)(C)OC(=O)N1CCC(C(NC(=O)c2ccc(-c3ccc(Nc4nc5ccc(F)cc5s4)cc3)cc2)C(=O)O)CC1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DGAT1 O75907 3/20 0.59
CSGALNACT1 Q8TDX6 1/20 0.59
MMP13 P45452 11/20 0.50
SMYD3 Q9H7B4 1/20 0.45
DYRK2 Q92630 1/20 0.44
MAPT P10636 3/20 0.44
HPGD P15428 3/20 0.44
SMN1; SMN2 Q16637 3/20 0.44
KDM4E B2RXH2 2/20 0.44
MEN1 O00255 2/20 0.44
LMNA P02545 2/20 0.44
KMT2A Q03164 2/20 0.44
ALDH1A1 P00352 2/20 0.44
USP2 O75604 1/20 0.44
ESR1 P03372 1/20 0.44
HSD17B10 Q99714 1/20 0.44
MMP1 P03956 3/20 0.42
MMP3 P08254 3/20 0.42
MMP7 P09237 3/20 0.42
MMP9 P14780 3/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1761696 0.92 DGAT1 (0.56) DGAT1CSGALNACT1MMP13SMYD3DYRK2
SCHEMBL1761627 0.84 DGAT1 (0.68) DGAT1CSGALNACT1MAPTHPGDSMN1; SMN2
SCHEMBL1762129 0.84 DGAT1 (0.67) DGAT1CSGALNACT1SMYD3MAPTHPGD
SCHEMBL1761993 0.79 DGAT1 (0.62) DGAT1CSGALNACT1MAPTHPGDSMN1; SMN2
SCHEMBL1761846 0.78 DGAT1 (0.78) DGAT1CSGALNACT1MAPTHPGDSMN1; SMN2
SCHEMBL1761653 0.77 DGAT1 (0.82) DGAT1CSGALNACT1MAPTHPGDSMN1; SMN2
SCHEMBL1761332 0.76 DGAT1 (0.75) DGAT1CSGALNACT1MAPTHPGDSMN1; SMN2
SCHEMBL4145628 0.76 DGAT1 (0.45) DGAT1CSGALNACT1DYRK2MAPTHPGD
SCHEMBL161989 0.75 DGAT1 (1.00) DGAT1CSGALNACT1MAPTHPGDSMN1; SMN2
SCHEMBL1762016 0.75 DGAT1 (0.73) DGAT1CSGALNACT1MAPTHPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110118302-A1 PREPARATION AND USE OF BIPHENYL-4-YL-CARBONYLAMINO ACID DERIVATIVES FOR THE TREATMENT OF OBESITY BAYER PHARMACEUTICALS CORPORATION (US) 2011-05-19 US claimed
EP-1805156-B1 PREPARATION AND USE OF BIPHENYL-4-YL-CARBONYLAMINO ACID DERIVATIVES FOR THE TREATMENT OF OBESITY BAYER HEALTHCARE LLC (US) 2010-12-22 EP claimed
US-7759376-B2 Preparation and use of biphenyl-4-yl-carbonylamino acid derivatives for the treatment of obesity BAYER HEALTHCARE LLC (US) 2010-07-20 US claimed
US-20070265298-A1 Preparation and Use of Biphenyl-4-Yl-Carbonylamino Acid Derivatives for the Treatment of Obesity BAYER PHARMACEUTICALS CORPORATION (US) 2007-11-15 US claimed
US-7759376-B2 Preparation and use of biphenyl-4-yl-carbonylamino acid derivatives for the treatment of obesity BAYER HEALTHCARE LLC (US) 2010-07-20 US disclosed
US-20070265298-A1 Preparation and Use of Biphenyl-4-Yl-Carbonylamino Acid Derivatives for the Treatment of Obesity BAYER PHARMACEUTICALS CORPORATION (US) 2007-11-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070265298-A1 Preparation and Use of Biphenyl-4-Yl-Carbonylamino Acid Derivatives for the Treatment of Obesity FABP4, GPR119, PGC DGAT1 486/4885CSGALNACT1 3157/4885MMP13 1170/4885
US-20110118302-A1 PREPARATION AND USE OF BIPHENYL-4-YL-CARBONYLAMINO ACID DERIVATIVES FOR THE TREATMENT OF OBESITY FABP4, GPR119, PGC DGAT1 486/4885CSGALNACT1 3157/4885MMP13 1170/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.